Dr. Girda is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany St
New Brunswick, NJ 08901Phone+1 732-235-7258
Education & Training
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Obstetrics and Gynecology, 2010 - 2014
Stony Brook University Health Sciences Center School of MedicineClass of 2010
University of California Davis HealthFellowship, Gynecologic Oncology
Certifications & Licensure
CA State Medical License 2014 - Present
NJ State Medical License 2017 - 2025- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies Start of enrollment: 2014 Oct 27
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Start of enrollment: 2015 Dec 18
- A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2016 Oct 31
- Join now to see all
Publications & Presentations
PubMed
- Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892).Sarah E Taylor, Sarah Behr, Kristine L Cooper, Haider Mahdi, Denise Fabian
Cancer Chemotherapy and Pharmacology. 2024-12-14 - 4 citationsPersonalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer.Olga B Garbuzenko, Justin Sapiezynski, Eugenia Girda, Lorna Rodriguez-Rodriguez, Tamara Minko
Small. 2024-10-01 - 1 citationsLenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.Antonio González-Martín, Hyun Cheol Chung, Esma Saada-Bouzid, Eduardo Yanez, Helene Senellart
Gynecologic Oncology. 2024-07-01
Press Mentions
Splash Pharmaceuticals Announces Clinical Trial Presentation at the 2018 American Society of Clinical Oncology Annual MeetingMay 29th, 2018
Experts Address the Latest on Cervical Cancer TreatmentJanuary 26th, 2024
Professional Memberships
- Socitey of Gynecologic OncologyMember
Other Languages
- Russian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
